Literature DB >> 18182677

Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?

Leen De Maeyer, Erik Van Limbergen, Katelijne De Nys, Philippe Moerman, Nathalie Pochet, Wouter Hendrickx, Hans Wildiers, Robert Paridaens, Ann Smeets, Marie-Rose Christiaens, Ignace Vergote, Karin Leunen, Frederic Amant, Patrick Neven.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18182677     DOI： 10.1200/JCO.2007.14.8411

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  34 in total

1.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

2.  Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.

Authors:  N Wu; F Fu; L Chen; Y Lin; P Yang; C Wang
Journal:  Clin Transl Oncol       Date:  2019-06-20       Impact factor: 3.405

3.  Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.

Authors:  Marina Gándara-Cortes; Ángel Vázquez-Boquete; Beatriz Fernández-Rodríguez; Patricia Viaño; Dora Ínsua; Alejandro Seoane-Seoane; Francisco Gude; Rosalía Gallego; Máximo Fraga; José R Antúnez; Teresa Curiel; Eva Pérez-López; Tomás García-Caballero
Journal:  Virchows Arch       Date:  2017-08-20       Impact factor: 4.064

Review 4.  Deciphering the divergent roles of progestogens in breast cancer.

Authors:  Jason S Carroll; Theresa E Hickey; Gerard A Tarulli; Michael Williams; Wayne D Tilley
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

5.  Estrogen receptor negative and progesterone receptor positive breast carcinomas-how frequent are they?

Authors:  Gábor Cserni; Monika Francz; Endre Kálmán; Gyöngyi Kelemen; Detre Csaba Komjáthy; Ilona Kovács; Janina Kulka; László Sarkadi; Nóra Udvarhelyi; László Vass; András Vörös
Journal:  Pathol Oncol Res       Date:  2011-01-26       Impact factor: 3.201

6.  Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.

Authors:  Kathleen Van Asten; Laurence Slembrouck; Siel Olbrecht; Lynn Jongen; Olivier Brouckaert; Hans Wildiers; Giuseppe Floris; Erik Van Limbergen; Caroline Weltens; Ann Smeets; Robert Paridaens; Anita Giobbie-Hurder; Meredith M Regan; Giuseppe Viale; Beat Thürlimann; Ignace Vergote; Evangelia Christodoulou; Ben Van Calster; Patrick Neven
Journal:  Oncologist       Date:  2018-08-31

Review 7.  Steroid hormone receptors as prognostic markers in breast cancer.

Authors:  Maggie C Louie; Mary B Sevigny
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

8.  Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.

Authors:  Jieqiong Liu; Wen Jiang; Kai Mao; Yi An; Fengxi Su; Betty Y S Kim; Qiang Liu; Lisa K Jacobs
Journal:  Breast Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.872

9.  Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.

Authors:  Katrina Bauer; Carol Parise; Vincent Caggiano
Journal:  BMC Cancer       Date:  2010-05-21       Impact factor: 4.430

10.  Re-Appraisal of Estrogen Receptor Negative/Progesterone Receptor Positive (ER-/PR+) Breast Cancer Phenotype: True Subtype or Technical Artefact?

Authors:  Niamh M Foley; J M Coll; A J Lowery; S O Hynes; M J Kerin; M Sheehan; C Brodie; K J Sweeney
Journal:  Pathol Oncol Res       Date:  2017-09-11       Impact factor: 3.201
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.